Halozyme to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Halozyme Therapeutics (NASDAQ: HALO) has announced its upcoming participation in two major investor conferences. The company's CEO, Dr. Helen Torley, will attend the Benchmark 2025 Healthcare House Call Virtual Conference on May 29, 2025, for one-on-one meetings. Additionally, she will participate in a fireside chat and investor meetings at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9, 2025, at 7:00 AM PT / 10:00 AM ET.

The presentation at the Goldman Sachs conference will be available via live audio webcast in the Investor Relations section of Halozyme's website, with replays accessible for 90 days after the event.

SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences.

Details on the Company's participation are as follows:

Event:				Benchmark 2025 Healthcare House Call Virtual Conference
Format:				1x1 Meetings
Date:				Thursday, May 29, 2025
Event:				Goldman Sachs 46th Annual Global Healthcare Conference 2025
Format:				Fireside Chat and 1x1 Meetings
Date:				Monday, June 9, 2025
Presentation Time:				7:00am PT / 10:00am ET

 

A live audio webcast of the presentation will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE^® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex^® and XYOSTED^®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-at-upcoming-investor-conferences-302467398.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When is Halozyme (HALO) presenting at the Goldman Sachs Healthcare Conference 2025?

Halozyme will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025, at 7:00 AM PT / 10:00 AM ET.

Who will represent Halozyme (HALO) at the upcoming investor conferences?

Dr. Helen Torley, president and chief executive officer of Halozyme, will represent the company at both conferences.

Which investor conferences will Halozyme (HALO) attend in May-June 2025?

Halozyme will attend the Benchmark Healthcare House Call Virtual Conference on May 29, 2025, and the Goldman Sachs Global Healthcare Conference on June 9, 2025.

How can investors access Halozyme's (HALO) presentation at the Goldman Sachs conference?

Investors can access the live audio webcast through the Investor Relations section of Halozyme's website, with replays available for 90 days after the conference.